AbClon, Inc.

As of June 30, 2026, AbClon, Inc. carries a market capitalization of 553.93B, placing it among publicly traded companies globally. Its enterprise value stands at 525.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, AbClon, Inc. has 19.93M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 101.78, and the price-to-book ratio stands at 10.50.

These figures are as of June 30, 2026. The EV/Sales ratio of 98.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 525.29B versus a market cap of 553.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AbClon, Inc. maintains a current ratio of 3.89, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.02, indicating elevated leverage, while an interest coverage ratio of -51.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AbClon, Inc. posted a negative return on equity (ROE) of -41.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.90, reflecting losses generated across the asset base. The company generates approximately 81.34M in revenue per employee across its workforce of 65.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.07 indicates how many times AbClon, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, AbClon, Inc.'s stock has gained approximately 24.71% over the past 52 weeks. The 50-day moving average sits at 24,518.00, while the 200-day moving average is 41,235.00.

Over the twelve months ended June 30, 2026, AbClon, Inc. generated 5.31B in revenue and converted that into -17.42B in net income, yielding earnings per share of -896.64. EBITDA reached -17.00B, while operating income came in at -17.86B.

As of June 30, 2026, AbClon, Inc. holds 36.38B in cash and equivalents against 7.44B in total debt, resulting in a net debt position of -23.38B. Total book value stands at 52.77B, with working capital of 29.44B providing operational flexibility.

AbClon, Inc. produced -13.64B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -208.19M in capital expenditures, free cash flow totaled -13.85B - equivalent to -712.82 per share.

Over the twelve months ended June 30, 2026, AbClon, Inc. posted a gross margin of 12.66, reflecting its pricing power and cost economics. The operating margin of -336.44 and net profit margin of -328.26 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.56: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.64, meaning AbClon, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AbClon, Inc.'s most recent stock split took place on July 16, 2020 with a 1:2 split ratio.

As of June 30, 2026, AbClon, Inc. has an Altman Z-Score of 26.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.